> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Awarded to Amryt Pharma
- URL: https://www.fdaweb.com/priority-voucher-awarded-to-amryt-pharma/
- Published: 2024-01-10T12:00:00.000Z
- Updated: 2026-09-14T14:19:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156116

*Federal Register* notice: FDA is announcing the issuance of a priority review voucher to Amryt Pharmaceuticals for its qualified rare pediatric disease product application — Filsuvez (birch triterpenes), indicated for treating partial thickness wounds in patients six months and older with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-00400.pdf?ref=fdaweb.com).